Enrolling

A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

I7P-MC-DSAF -

This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development.

Enter your city or zip code to find the nearest site

Trial Summary

Age Range
18 - 75 years
Conditions the trial is for
Hidradenitis Suppurativa
What the trial is testing?
Eltrekibart
Could I receive a Placebo?
Yes
Enrollment Goal
350
Trial Dates
Oct 23, 2023 - Jul 2026
How long will I be in the trial?
The study will last about 62 weeks and may include up to 31 visits.
Trial Phase
II

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Be age 18-75

  • Have HS for at least 12 months

  • Have HS lesions in at least 2 different parts of the body

  • Have not responded to or tolerated 28-day course of oral antibiotics

  • Agree to use topical antiseptics daily

Participants Must Not:

  • Have had surgical treatment for HS in the last 4 weeks before randomization

  • Have an active skin disease or condition that could interfere with the assessment of HS

  • Be immunocompromised

  • Have a history of chronic alcohol abuse or drug abuse or other illicit drug abuse 1 year before screening

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources